Prostanoids play an important role in a variety of physiological and pathophysiological processes including inflammation and cancer. The rate-limiting step in the prostanoid biosynthesis pathway is catalyzed by cyclooxygenase-2 (COX-2). COX-2 exists as two glycoforms, 72 and 74 kDa, the latter resulting from an additional glycosylation at Asn(580). In this study, Asn(580) was mutated, and the mutant and wild-type COX-2 genes were expressed in COS-1 cells to determine how glycosylation affects the inhibition of COX-2 activity by aspirin, flurbiprofen, ibuprofen, celecoxib, and etoricoxib. Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors.
Cyclooxygenase‐2 (COX‐2) is an enzyme that catalyzes the rate‐limiting step in the prostanoid synthesis pathway, which plays an important role in a variety of physiological and pathophysiological processes including inflammation and cancer. COX‐2 exists as two major glycoforms of 72 and 74kDa, the latter resulting from an additional oligosaccharide chain at amino acid residue Asn580. The purpose of this study is to determine if this additional glycosylation affects the inhibitory ability of various COX‐2 inhibitors. COS‐1 cells were transiently transfected with either the wild‐type or Asn580‐mutant COX‐2 gene. Subsets of both cell groups were treated with various concentrations of either Aspirin, Flurbiprofen, Ibuprofen, or Celecoxib. After addition of the COX‐2 substrate arachidonic acid to inhibitor‐treated and untreated (control) cells, media was collected and subjected to an ELISA which measured levels of the downstream product prostaglandin E2. Results indicate that, at low concentrations, all of the inhibitors seem to have a greater effect on the 70/72 kDa glycoform. However, the effects of aspirin and flurbiprofen were less profound. This indicates that glycosylation of COX‐2 at Asn580 influences the efficacy of COX‐2 inhibitors.
Cyclooxygenase‐2 (COX‐2) is an enzyme that catalyzes the rate‐limiting step in the prostanoid synthesis pathway, which plays an important role in a variety of physiological and pathophysiological processes including inflammation and cancer. COX‐2 exists as two major glycoforms of 72 and 74kDa, the latter resulting from an additional oligosaccharide chain at amino acid residue Asn580. The purpose of this study is to determine if this additional glycosylation affects the inhibitory ability of various COX‐2 inhibitors. COS‐1 cells were transiently transfected with either the wild‐type or Asn580‐mutant COX‐2 gene. Subsets of both cell groups were treated with various concentrations of either aspirin, flurbiprofen, ibuprofen, or celecoxib. After addition of the COX‐2 substrate arachidonic acid to inhibitor‐treated and untreated (control) cells, media was collected and subjected to an ELISA which measured levels of the downstream product prostaglandin E2. Results indicate that, at low concentrations, both aspirin and flurbiprofen are more effective at inhibiting the activity of the 72 than the 74 kDa glycoform, whereas ibuprofen and celecoxib are more effective at inhibiting the 74 kDa glycoform. This indicates that glycosylation of COX‐2 at Asn580 influences the efficacy of COX‐2 inhibitors.Research supported by the Dept. of Natural Sciences and Mathematics at Dominican University of California.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.